Clay Siegall is one of the co-founders of Seattle Genetics. The company was founded in 1998 and he currently serves as the President and CEO as well as serving as Chairman Of The Board. He has used his extensive scientific background to help create a treatment for those individuals that are suffering from cancer. He has helped to develop a very successful treatment that is currently their best seller and revenue creator called Adcetris. It is available globally and is available in sixty countries. The drug was approved in 2011 and continues to be the most popular offering the company has right now. There are also other cancer treatments in the works.
Dr. Siegall has been able to lead the company to a great deal of success and he has also been able to obtain licenses for ADC technology. Some of the licenses were issued to industry giants such as Pfizer, GlaxoSmithKline, and AbbVie. The licenses have been able to create revenue that exceeds $325 million. Much of Dr.Siegall’s focus has been on raising money for further development and research. He has been able to single-handedly raise over $1.2 billion which includes private and public funds.
Before he helped to co-found Seattle Genetics, Dr. Clay Siegall was working for Bristol-Myers Squibb Pharmaceutical Research Institute. He also worked for the National Institute of Health and the National Cancer Institute. In addition to serving in several capacities for Seattle Genetics, Dr. Clay Siegall also serves on the Board Of Directors for Utragenyx Pharmaceutical, Mirna Therapeutics, Alder BioPharmaceuticals, and Washington Roundtable. Dr. Siegall brings a whole wealth of dedication and knowledge to each company that he has a hand in guiding. He takes great pride in being able to help those individuals that were not helped by other forms of treatment.